Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL

Bookmark and Share
Published: 6 Dec 2018
Views: 493
Rating:
Save
Dr Tait Shanafelt - Standford University, Stanford, USA

Dr Tait Shanafelt gives a press conference at ASH 2018 on the findings of the E1912 which show the combination of ibrutinib and rituximab to be superior to FCR chemoimmunotherapy for younger patients with previously untreated CLL.

Watch his interview with ecancer here.

Read more about this work here.